Covishield Vaccine Trial
- All
- News
- Videos
-
Biological E Seeks Regulator's Nod For Phase-3 Trial Of Booster Dose
Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.
-
Vaccination Certificates Via CoWIN For Covishield, Covaxin Trial Participants
The participants in the clinical trials of Covishield and Covaxin have received their Covid vaccination certificates through the CoWIN app, the Centre has said. Union Health Minister Mansukh Mandaviya thanked their contribution during the pandemic.
-
Covaxin's Phase 3 Trial Results Will Be Out In July, Says Bharat Biotech
Once the results of Covaxin's phase 3 trials are out in July, its manufacturers have scheduled a phase 4 trial to test the vaccines real-world effectiveness, Bharat Biotech said today.
-
Russian Covid Vaccine Sputnik Could Be Available In India By April: 10 Points
Russian-made Coronavirus vaccine Sputnik -- peer-reviewed by the Lancet Medical Journal -- is undergoing trials in India and could be available for use soon. "I believe the vaccine should be available in India from March- April," Deepak Sapra, the chief of API and pharma services at Dr Reddy's Laboratories, which is manufacturing the vaccine, told...
-
Give Option To Choose Vaccine: Karnataka Resident Doctors To Centre
The president of the Karnataka Association of Resident Doctors, Dr Dayanand Sagar on Tuesday raised concern over the COVID-19 vaccine Covaxin.
-
"Will Prefer Covishield Over Covaxin": Delhi Hospital Doctors Concerned
Resident doctors at one of Delhi's biggest healthcare hubs, the Ram Manohar Lohia Hospital, on Saturday demanded they be administered Covishield vaccine and not Covaxin since the former has completed all three stages of trials as required under protocol. The second one, produced by Hyderabad-based Bharat Biotech, is still only undergoing stage-III ...
-
Bharat Biotech Enrols Over 25,000 Volunteers For Covaxin Phase 3 Trial
Bharat Biotech has enrolled 25,800 volunteers for phase 3 clinical trials of its COVID-19 vaccine, the company said today. The maker of Covaxin is one of the two firms cleared by the government to deploy their product for mass inoculation in the country. The other is Oxford-AstraZeneca's Covishield manufactured by the Serum Institute of India.
-
Serum Institute's 100-Crore Case After Man Says Vaccine Made Him Ill
The Serum Institute responded to "malicious and mischievous" allegations by preparing a Rs 100 crore defamation suit against a coronavirus vaccine trial participant who claimed a "virtual neurological breakdown" after being given a dose
-
Oxford Vaccine "Could Be Realistic Solution" To Covid: Medical Body ICMR
The Pune-based Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) on Thursday announced the completion of enrolment of phase-3 clinical trials for potential COVID-19 vaccine Covishield in India.
-
"Don't Agree With Rs 80,000 Crore Figure For COVID Vaccine Distribution": Centre
The Union Health Ministry has said it does not agree with the Rs 80,000 crore figure cited by Adar Poonawalla, CEO of Serum Institute of India - the world's largest manufacturer of vaccines by volume and which is conducting trials of Covid vaccine candidates ahead of mass production - for buying and distributing the vaccine in the country. The Mini...
-
"Will Centre Have 80,000 Crore For Covid Vaccines" Adar Poonawalla Asks
Adar Poonawalla, the CEO of the Serum Institute of India - the world's largest manufacturer of vaccines by volume and which is conducting Covid vaccine trials ahead of mass production - took to Twitter to highlight potential challenges ahead of vaccine production and distribution
-
2 Mumbai Hospitals Begin Phase 2, 3 Trials Of Oxford Covishield Vaccine For COVID-19: Report
The civic-run King Edward Memorial (KEM) Hospital in Mumbai today began phase II and III trials of the Oxford Covishield vaccine for COVID-19, an official said.
-
Phase 3 Trial Of Oxford Vaccine To Begin In Pune Next Week
The phase-III human clinical trial of the COVID-19 vaccine developed by Oxford University, and being manufactured by the Serum Institute of India (SII), will begin at the Sassoon General Hospital in Pune next week.
-
Adar Poonawalla's Serum Institute Told To Pause Vaccine Trial Recruitment
New recruitment for the Phase 2 and Phase 3 trials of the Oxford University's Covishield vaccine being manufactured in India by the Serum Institute of India, along with pharma major AstraZeneca, has to be suspended till further orders, country's drug controller DCGI has said.
-
Serum Institute To Pause Vaccine Trials In India After Drug Controller's Notice
Serum Institute of India, which is manufacturing the coronavirus vaccine Covishield being developed by the Oxford University along with pharma major AstraZenca, today said it will stop the Phase 3 trials that were to begin in India next week. The vaccine trial was stopped across four nations as a precautionary measure after one of the recipients in...
-
Biological E Seeks Regulator's Nod For Phase-3 Trial Of Booster Dose
Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.
-
Vaccination Certificates Via CoWIN For Covishield, Covaxin Trial Participants
The participants in the clinical trials of Covishield and Covaxin have received their Covid vaccination certificates through the CoWIN app, the Centre has said. Union Health Minister Mansukh Mandaviya thanked their contribution during the pandemic.
-
Covaxin's Phase 3 Trial Results Will Be Out In July, Says Bharat Biotech
Once the results of Covaxin's phase 3 trials are out in July, its manufacturers have scheduled a phase 4 trial to test the vaccines real-world effectiveness, Bharat Biotech said today.
-
Russian Covid Vaccine Sputnik Could Be Available In India By April: 10 Points
Russian-made Coronavirus vaccine Sputnik -- peer-reviewed by the Lancet Medical Journal -- is undergoing trials in India and could be available for use soon. "I believe the vaccine should be available in India from March- April," Deepak Sapra, the chief of API and pharma services at Dr Reddy's Laboratories, which is manufacturing the vaccine, told...
-
Give Option To Choose Vaccine: Karnataka Resident Doctors To Centre
The president of the Karnataka Association of Resident Doctors, Dr Dayanand Sagar on Tuesday raised concern over the COVID-19 vaccine Covaxin.
-
"Will Prefer Covishield Over Covaxin": Delhi Hospital Doctors Concerned
Resident doctors at one of Delhi's biggest healthcare hubs, the Ram Manohar Lohia Hospital, on Saturday demanded they be administered Covishield vaccine and not Covaxin since the former has completed all three stages of trials as required under protocol. The second one, produced by Hyderabad-based Bharat Biotech, is still only undergoing stage-III ...
-
Bharat Biotech Enrols Over 25,000 Volunteers For Covaxin Phase 3 Trial
Bharat Biotech has enrolled 25,800 volunteers for phase 3 clinical trials of its COVID-19 vaccine, the company said today. The maker of Covaxin is one of the two firms cleared by the government to deploy their product for mass inoculation in the country. The other is Oxford-AstraZeneca's Covishield manufactured by the Serum Institute of India.
-
Serum Institute's 100-Crore Case After Man Says Vaccine Made Him Ill
The Serum Institute responded to "malicious and mischievous" allegations by preparing a Rs 100 crore defamation suit against a coronavirus vaccine trial participant who claimed a "virtual neurological breakdown" after being given a dose
-
Oxford Vaccine "Could Be Realistic Solution" To Covid: Medical Body ICMR
The Pune-based Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) on Thursday announced the completion of enrolment of phase-3 clinical trials for potential COVID-19 vaccine Covishield in India.
-
"Don't Agree With Rs 80,000 Crore Figure For COVID Vaccine Distribution": Centre
The Union Health Ministry has said it does not agree with the Rs 80,000 crore figure cited by Adar Poonawalla, CEO of Serum Institute of India - the world's largest manufacturer of vaccines by volume and which is conducting trials of Covid vaccine candidates ahead of mass production - for buying and distributing the vaccine in the country. The Mini...
-
"Will Centre Have 80,000 Crore For Covid Vaccines" Adar Poonawalla Asks
Adar Poonawalla, the CEO of the Serum Institute of India - the world's largest manufacturer of vaccines by volume and which is conducting Covid vaccine trials ahead of mass production - took to Twitter to highlight potential challenges ahead of vaccine production and distribution
-
2 Mumbai Hospitals Begin Phase 2, 3 Trials Of Oxford Covishield Vaccine For COVID-19: Report
The civic-run King Edward Memorial (KEM) Hospital in Mumbai today began phase II and III trials of the Oxford Covishield vaccine for COVID-19, an official said.
-
Phase 3 Trial Of Oxford Vaccine To Begin In Pune Next Week
The phase-III human clinical trial of the COVID-19 vaccine developed by Oxford University, and being manufactured by the Serum Institute of India (SII), will begin at the Sassoon General Hospital in Pune next week.
-
Adar Poonawalla's Serum Institute Told To Pause Vaccine Trial Recruitment
New recruitment for the Phase 2 and Phase 3 trials of the Oxford University's Covishield vaccine being manufactured in India by the Serum Institute of India, along with pharma major AstraZeneca, has to be suspended till further orders, country's drug controller DCGI has said.
-
Serum Institute To Pause Vaccine Trials In India After Drug Controller's Notice
Serum Institute of India, which is manufacturing the coronavirus vaccine Covishield being developed by the Oxford University along with pharma major AstraZenca, today said it will stop the Phase 3 trials that were to begin in India next week. The vaccine trial was stopped across four nations as a precautionary measure after one of the recipients in...
